Whitehawk Therapeutics Inc
WHWK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.00 | -0.03 |
| FCF Yield | 0.00% | -40.99% | -25.75% | -17.80% |
| EV / EBITDA | -5.17 | 0.30 | 11.82 | -3.17 |
| Quality | ||||
| ROIC | -12.44% | -31.82% | -6.86% | -35.41% |
| Gross Margin | 0.00% | 0.00% | 89.36% | -109.10% |
| Cash Conversion Ratio | 1.01 | -0.16 | 0.82 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.80% | 0.09% | 13.94% | 19.53% |
| Free Cash Flow Growth | 0.00% | -326.56% | 18.53% | 4.01% |
| Safety | ||||
| Net Debt / EBITDA | 2.14 | 2.76 | 15.00 | 1.53 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 2.85 |
| Cash Conversion Cycle | -29,394.00 | 0.00 | -433.07 | 92.13 |